scholarly journals In Vitro Activity of Levofloxacin against a Selected Group of Anaerobic Bacteria Isolated from Skin and Soft Tissue Infections

1998 ◽  
Vol 42 (4) ◽  
pp. 984-986 ◽  
Author(s):  
Hannah M. Wexler ◽  
Eric Molitoris ◽  
Denise Molitoris ◽  
Sydney M. Finegold
Keyword(s):  
Soft Tissue ◽  
Clinical Laboratory ◽  
Geometric Mean ◽  
Anaerobic Bacteria ◽  
Vitro Activity ◽  
National Committee ◽  
Soft Tissue Infections ◽  
In Vitro Activity ◽  
Select Group

ABSTRACT The in vitro activity of levofloxacin was compared to the activities of ofloxacin, ciprofloxacin, ampicillin-sulbactam (2:1), cefoxitin, and metronidazole for a selected group of anaerobes (n = 175) isolated from skin and soft tissue infections by using the National Committee for Clinical Laboratory Standards-approved Wadsworth method. Ampicillin-sulbactam and cefoxitin inhibited 99% of the strains of this select group, levofloxacin and ofloxacin inhibited 73 and 50%, respectively, at 2 μg/ml, and ciprofloxacin inhibited 51% at 1 μg/ml. The geometric mean MIC of levofloxacin was lower than those of ofloxacin and ciprofloxacin for every group except Veillonella.

scholarly journals In Vitro Activity of Ceftaroline against 623 Diverse Strains of Anaerobic Bacteria

2010 ◽  
Vol 54 (4) ◽  
pp. 1627-1632 ◽  
Author(s):  
D. M. Citron ◽  
K. L. Tyrrell ◽  
C. V. Merriam ◽  
E. J. C. Goldstein
Keyword(s):  
Soft Tissue ◽  
Broad Spectrum ◽  
Anaerobic Bacteria ◽  
Soft Tissue Infections ◽  
Good Activity ◽  
In Vitro Activity ◽  
Gram Negative ◽  
Amoxicillin Clavulanate ◽  
Gram Negative Organisms

ABSTRACT The in vitro activities of ceftaroline, a novel, parenteral, broad-spectrum cephalosporin, and four comparator antimicrobials were determined against anaerobic bacteria. Against Gram-positive strains, the activity of ceftaroline was similar to that of amoxicillin-clavulanate and four to eight times greater than that of ceftriaxone. Against Gram-negative organisms, ceftaroline showed good activity against β-lactamase-negative strains but not against the members of the Bacteroides fragilis group. Ceftaroline showed potent activity against a broad spectrum of anaerobes encountered in respiratory, skin, and soft tissue infections.

scholarly journals In Vitro Activity of Syn-2869, a Novel Triazole Agent, against Emerging and Less Common Mold Pathogens

1999 ◽  
Vol 43 (5) ◽  
pp. 1260-1263 ◽  
Author(s):  
Elizabeth M. Johnson ◽  
Adrien Szekely ◽  
David W. Warnock
Keyword(s):  
Amphotericin B ◽  
Clinical Laboratory ◽  
Sporothrix Schenckii ◽  
Vitro Activity ◽  
National Committee ◽  
In Vitro Activity ◽  
Absidia Corymbifera ◽  
Scopulariopsis Brevicaulis ◽  
Cladophialophora Carrionii

ABSTRACT The in vitro activity of Syn-2869 was compared with that of amphotericin B and itraconazole. MICs for 100 isolates of pathogenic molds belonging to 12 species were determined by a broth microdilution adaptation of the method recommended by the National Committee for Clinical Laboratory Standards. Syn-2869 and itraconazole showed comparable, good activity against the dematiaceous moldsCladophialophora bantiana, Cladophialophora carrionii, Exophiala dermatitidis, Fonsecaea pedrosoi, Phialophora parasitica, andRamichloridium mackenziei. Neither of the azole agents was active against the hyaline molds Fusarium solani,Scedosporium prolificans, and Scopulariopsis brevicaulis, but both were more active than amphotericin B against Scedosporium apiospermum. The MICs of the three agents were comparable for the mucoraceous moldAbsidia corymbifera, but Syn-2869 appeared to be the least active against the dimorphic mold Sporothrix schenckii. Our results suggest that Syn-2869 could be effective against a range of mold infections in humans.

scholarly journals In Vitro Activity of A-192411.29, a Novel Antifungal Lipopeptide

2000 ◽  
Vol 44 (5) ◽  
pp. 1242-1246 ◽  
Author(s):  
Angela M. Nilius ◽  
Patti M. Raney ◽  
Dena M. Hensey-Rudloff ◽  
Weibo Wang ◽  
Qun Li ◽  
...  
Keyword(s):  
Amphotericin B ◽  
Clinical Laboratory ◽  
Vitro Activity ◽  
National Committee ◽  
In Vitro Activity ◽  
Microdilution Method ◽  
Broth Microdilution Method ◽  
Structural Template ◽  
Better Than

ABSTRACT A-192411.29 is a novel antifungal agent derived from the structural template of the natural product echinocandin. The in vitro activity of A-192411.29 against common pathogenic yeasts was assessed by National Committee for Clinical Laboratory Standards method M27-A. It demonstrated broad-spectrum, fungicidal activity and was active against the most clinically relevant yeasts, such as Candida albicans, Candida tropicalis, and Candida glabrata, as well as less commonly encounteredCandida species; in general, its potency on a weight basis was comparable to that of amphotericin B. It maintained potent in vitro activity against Candida strains with reduced susceptibilities to fluconazole and amphotericin B. The in vitro activity of A-192411.29 against Cryptococcus neoformans was comparable to its activity against Candida spp. However, A-192411.29 did not demonstrate complete growth inhibition ofAspergillus fumigatus by the broth microdilution method used. A-192411.29 possesses an antifungal profile comparable to or better than those of fluconazole and amphotericin B against pathogenic yeasts, including strains resistant to fluconazole or amphotericin B, suggesting that it may be a therapeutically useful new antifungal drug.

scholarly journals In Vitro Activities of 5-Fluorocytosine against 8,803 Clinical Isolates of Candida spp.: Global Assessment of Primary Resistance Using National Committee for Clinical Laboratory Standards Susceptibility Testing Methods

2002 ◽  
Vol 46 (11) ◽  
pp. 3518-3521 ◽  
Author(s):  
M. A. Pfaller ◽  
S. A. Messer ◽  
L. Boyken ◽  
H. Huynh ◽  
R. J. Hollis ◽  
...  
Keyword(s):  
Clinical Laboratory ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
National Committee ◽  
In Vitro Activity ◽  
Candida Spp ◽  
Primary Resistance ◽  
Antifungal Effect ◽  
Medical Centers

ABSTRACT We determined the in vitro activity of flucytosine (5-fluorocytosine [5FC]) against 8,803 clinical isolates of Candida spp. (18 species) obtained from more than 200 medical centers worldwide between 1992 and 2001. The MICs were determined by broth microdilution tests performed according to NCCLS guidelines by using RPMI 1640 as the test medium and the following interpretive breakpoints: susceptible (S), ≤4 μg/ml; intermediate (I), 8 to 16 μg/ml; resistant (R), ≥32 μg/ml. 5FC was very active against the 8,803 Candida isolates (MIC90, 1 μg/ml), 95% S. A total of 99 to 100% of C. glabrata (MIC90, 0.12 μg/ml), C. parapsilosis (MIC90, 0.25 μg/ml), C. dubliniensis (MIC90, 0.12 μg/ml), C. guilliermondii (MIC90, 0.5 μg/ml), and C. kefyr (MIC90, 1 μg/ml) were susceptible to 5FC at the NCCLS breakpoint. C. albicans (MIC90, 1 μg/ml; 97% S) and C. tropicalis (MIC90, 1 μg/ml; 92% S) were only slightly less susceptible. In contrast, C. krusei was the least susceptible species: 5% S; MIC90, 32 μg/ml. Primary resistance to 5FC is very uncommon among Candida spp. (95% S, 2% I, and 3% R), with the exception of C. krusei (5% S, 67% I, and 28% R). The in vitro activity of 5FC, combined with previous data demonstrating a prolonged post-antifungal effect (2.5 to 4 h) and concentration-independent activity (optimized at 4× MIC), suggest that 5FC could be used in lower doses to reduce host toxicity while maintaining antifungal efficacy.

Sign in / Sign up

Export Citation Format

Share Document